WORLD JOURNAL OF PHARMACEUTICAL RESEARCH
SJIF Impact Factor 8.453
Volume 13, Issue 8, 299-313. Review Article ISSN 2277–7105

"A COMPREHENSIVE APPROACH: MANAGING DIABETES IN PREGNANCY FOR POSITIVE GESTATIONAL AND FETAL RESULTS"

Prashant Anil Kalokhe*, Rutuja Balu Gogade and Saloni Ganesh Songade

Lokmanya Tilak Institute of Pharmaceutical Sciences Mukund Nagar Gultekdi Pune, 411037.

Article Received on
21 February 2024,

Revised on 11 March 2024,
Accepted on 01 April 2024

DOI: 10.20959/wjpr20248-31959

***Corresponding Author**
Prashant Anil Kalokhe
Lokmanya Tilak Institute of Pharmaceutical Sciences
Mukund Nagar Gultekdi
Pune, 411037.

ABSTRACT

Gestational diabetes mellitus (GDM) and its effects on the health of mothers and their offspring are thoroughly studied in this overview studies. During the prenatal period, women without a history of diabetes develop persistent high blood sugar levels, a serious pregnancy condition known as gestational diabetes mellitus (GDM). Hyperglycaemias is primarily brought on by impaired glucose tolerance, which is a consequence of pancreatic beta cell failure in the context of long-term insulin resistance. A family history of any kind of diabetes, being overweight or obese, and being an older mother are associated risk factors for developing GDM. The implications of gestational diabetes mellitus include increased risk of type 2 diabetes and cardiovascular disease (CVD) in the mother's as well as macrosomia and difficulty delivering the baby. Furthermore, a longer-term. This study looked at the variations in new-born outcomes, birthing features, and complications during pregnancy between women with gestational diabetes while pregnant (GDM), type 1 diabetes mellitus (T1DM), and type 2 diabetes mellitus (T2DM). A condition known as and premature labour are both adverse gestation and new-born outcomes that must be reduced with a multi-target therapy. It is recommended to maintain strict glycaemic control in addition to normal gestational weight gain, lifestyle modifications, and, if required, low-dose aspirin and antihypertensive medication.

KEYWORDS: Obstetrical diabetes mellitus, a form of diabetes mellitus (dm), physical activity, medication for insulin, macrosomia, childbirth, overweight or obesity, and monitoring of blood glucose, pregnancy-related issues.

INTRODUCTION

Pregnant women lacking diabetes before to becoming pregnant could develop unexpectedly developed hyperglycaemia, which is a sign of gestation diabetes mellitus (GDM), which is a metabolic condition of pregnancy that often goes away afterwards delivering birth.[1]

There are a couple main forms of hyperglycaemia

1. Type 1 is a form of diabetes mellitus that is dependent on insulin (IDDM)

Low-birth-weight insulin Diabetes mellitus: Pancreatic islets are destroyed; most instances are autoimmune (type 1A), where antibodies that kill β cells are present across the blood; however, in some idiopathic (type 1B) cases, no β cell antibody is discovered. Patients having type 1 diabetes are more likely to have ketosis and have circulating insulin levels that are low or very low. This kind has a low level of inheritance & is less prevalent.

2. Non-insulin-dependent diabetes mellitus of type II

(NIDDM), or Mature-onset diabetes mellitus possesses a high degree of genetic vulnerability, usually develops late (after middle age), has no detectable anti-β-cell antibody, neither a loss of β cell mass nor a slight reduction in it, and has low, normal, or even high levels of insulin in the blood. Over 90% of instances of diabetes are type 2 DM. The causes could be as follows

- Deviation from the usual β cell glucose-receptor, causing the cells to react to elevated glucose concentrations or relative β cell shortage. Either way, there is a reduction in insulin secretion, which could lead to β cell failure.

- Decreased sensitivity (relative resistance); a decrease in the number of insulin receptors, or "down regulation," in peripheral tissues to insulin. In addition to being norm glycaemic but hyperinsulinemia, many hypertensives also have dyslipidaemia, hyperuricemia, and abdominal obesity (metabolic syndrome). Consequently, there is relative amongst the eight Millennium Development Goals (MDGs), which set forth by the United Nations are the enhancement of maternal health and the reduction of childhood mortality. They pose a distinct and difficult challenge to medical personnel across the globe.[2] Together with an increase in the rate of diabetes in the general population, there is a concerning rise in the overall incidence of hyperglycaemia during childbirth.

Effect on mother

Quickly if there are signs of rather significant decompensating, such as high glucose levels, evident insulin resistance, and reduced beta cell activity. Women with these features may have a minor decrease in their bodily condition before surpassing the glucose threshold that defines diabetes mellitus.[3] The chance of the mother getting diabetes shortly after being diagnosed with GDM. Thus, it makes sense to believe that GDM is a form of prediabetes that is comparable to non-pregnant the consequent effects of GDM on maternal health include a number of immediate and long-term concerns. Parental depression may be aggravated by GDM along with to the difficulty of a regular pregnancy.[4]

The higher probability of problems in subsequent pregnancies, including premature birth and hypertension, frequently requires a surgical delivery for the new-born.[5] Diabetes mellitus is considerably more likely to affect women with GDM in later age. Shortly after giving birth, diabetes mellitus develops in approximately 10 percent of women suffering from gestational diabetes mellitus.[6]

The remainder appear to get diabetes mellitus at rates of 20%–60% within 5–10 years after the index pregnancy if specific actions are not taken to reduce their risk of the condition. Limited long-term evidence from O'Sullivan indicates that not all women with gestational diabetes will acquire diabetes mellitus, but the majority will.[7] GDM increases the chance of postpartum diabetes mellitus, much like it does for pregnant problems. That being said, the chance of GDM causing complications during pregnancy is far less than individuals' hyperglycaemia.[8] As previously stated, a large number of patients with diabetes mellitus following GDM fit the pre-type 2 diabetes mellitus (T2DM) profile. Research on controlling the level of glucose after GDM over time reveals a decrease in beta cell adaptation for chronic insulin resistance; this may further worsen with time.[9] The condition diabetes mellitus can develop after childbirth quite.

At relatively high rates, weight gain, insulin resistance, rising C-reactive protein levels, and falling adiponectin levels are risk factors for beta cell degeneration due which results in diabetes mellitus.[10]

These results suggest that beta cell degeneration leading to diabetes mellitus is mostly caused by the metabolic effects of fat. As we'll discuss below, the best way to prevent T2DM from developing after GDM is to lessen the negative effects caused by obesity through diet and

exercise, or by taking medication that enhance the physical composition and function of the fat tissue in the body.[11] Metabolic syndrome, which includes obesity and other associated diseases, serves as the foundation upon which T2DM develops.[12] The probability of women with GDM displaying symptoms of metabolic syndrome is higher than it is for women without GDM (17) Recurrent episodes of GDM are also associated with a higher frequency of cardiovascular risk factors and cardiovascular events.[13] The majority of moms with GDM are fat, and a significant portion of the obese population also has GDM.[14]

Obstacles throughout Maternity

If the baby is exceptionally large, vaginal birth will be more difficult. There's a possibility of a protracted labour in which the baby becomes stuck in the birth canal, that an instrumental delivery (with forceps or a vacuum) is necessary, or that an unexpected or emergency caesarean section is necessary. In comparison to when the baby is of normal size, there is a higher chance of lacerations and rips of the vaginal tissue during birthing, as well as perinea tear (a tearing of the muscle between the vagina and the anus).[15]

In addition, the chance of uterine agony is considerable. The uterine muscle may not contract properly, leading to heavy bleeding and postpartum haemorrhage. There is a three- to five-fold higher risk of genital tract damage and haemorrhaging following delivery in macrocosmic new-borns.[16]

Impact and shortcomings during childbirth

Early delivery

Early labour induction (before 39 weeks and/or early rupture of the membrane) may result in preterm delivery. Despite all efforts to induce early birth, babies still face risks associated with preterm, including difficulty breathing and feeding, infections, jaundice, admission to the neonatal intensive care unit, and perinatal death. The prevalence of preterm delivery is approximately 10.6% globally when coupled with a number of other risk variables, such as pregnancy-related obesity and depression.[17]

Birth-related diabetes

GDM is not only bad for moms, but it is also bad for the foetus. Since the developing foetus can only create a limited amount of glucose, the mother's blood provides the majority of the glucose it needs. Maternal glucose crosses the placenta, but not maternal insulin. According to the modified Pedersen's theory, increased fatal insulin synthesis occurs from excess

glucose being carried across the placenta in high and uncontrolled maternal glucose levels, independent of glucose stimulation.

This is supported by the discovery that foetuses with insulin-dependent diabetes mellitus have greater placental expression of glucose transport proteins (GLUTs).[18]

Furthermore, it is well known that insulin can activate mTOR, a potent regulator of cell division. Raised maternal insulin stimulates the placenta's system A and system L amino acid transporters, which in turn increase placental mTOR activity and promote cell division and activation access to vital nutrients.[19]

Because of the previously described factors, maternal hyperglycaemia and hyperinsulinemia may generate changes in the foetus that are similar to those observed in GDM, which may lead to neonatal obesity.[20]

Abnormal nutrient storage leads to microsomal, or an increase in the size of the new-born. The fatal abdomen and shoulders are where most of the fat is concentrated. 15%–45% of a history of G pregnancies results in macrocosmic infants.

Erg's condition and shoulder instability

A number of the most dangerous outcomes of vaginal delivery, especially in macrocosmic new-borns, are shoulder dystocia, which is particularly connected with birth trauma. Birth trauma is six times more likely to occur in new-born weighing 4,500 g or more than in other new-born weight divisions.[21] Additionally, the risk of brachial plexus injury increases by about 20 times if the birth weight is greater than over 4,500 g.[22]

Hereditary Defects

Some of the most common birth defects are neural tube abnormalities involving spina bifida and cardiac issues. The growing foetus's destruction of organs brought on by the high blood sugar levels of GDM-afflicted women may culminate in congenital malformations.[23]

Issues during labour

Neonatal problems might include hypoxia, hypoglycaemia, kernicterus, jaundice, and birth trauma such as shoulder dystocia and a brachial plexus wound. Infections caused by germs and neonatal respiratory distress syndrome (NRDS) are possible additional ones.[24]

Juvenile conjunctivitis

Yellowing of the skin can be caused by a number of things, including prematurity, poor nutrition, and increased the circulatory system of bilirubin as a result of impaired hepatic conjugation of bilirubin. Macrosomia new-borns have a higher oxygen need, which causes erythropoiesis to rise and, eventually, a condition called poly.[25]

Diabetes that was present before

There are several classification schemes that have been put up for pregnancies among women who already have diabetes. Diabetes has been classified by Dr. Priscilla White (Peter H. Bennett).

It was designed to assist in predicting the outcomes of pregnancies and was based on the probability of having vascular disease. It is important to note that gestational diabetes was not included in the White categorization. According to White, the class an individual simply received dietary adjustments rather than insulin treatment despite having an abnormal glucose tolerance test before becoming pregnant. While every trainee in obstetrics and gynaecology used to learn the White classification scheme, its usefulness in clinical therapy is questionable nowadays. Every person who has diabetes mellitus and becomes pregnant should be regarded as having a high-risk pregnancy. Vascular illness obviously raises certain hazards for both mothers and foetuses, but its seeming lack of vascular illness is not something to feel comforted with. Pedersen's classification approach is an additional one.[27]

Diabetes-related healthcare problems

Nephropathic

Both type 1 and type 2 diabetes are made more difficult by overt diabetic nephropathy, which is often identified by albuminuria ≥300 mg/day. The prevalence of nephropathy is linked to the length of diabetes, however pregnant women with type 1 diabetes are significantly more likely to develop nephropathy than those with type 2 diabetes due to the latter's tendency to develop later in life. Nephropathy, or a urine protein excretion of ≥300 mg/day before the third trimester, was observed in 23 percent of pregnant women with pre-existing diabetes in one cohort from a tertiary care facility.[28]

Renal hypertrophy and hyper function characterize the first stage of nephropathy development, which is followed by renal lesions without clinical symptoms. Albuminuria does not appear until the subsequent stage, which happens in 7–15 years in 25–40% of people

with type 1 diabetes. By then, it is only micro albuminuria, ranging from 30–299 mg/day. The most practical method at the moment is to measure the spot urine albumin to creatinine ratio (UACR), with increased albumin excretion being described as ≥30 mg/g creatine.[29]

A person with microalbuminuria has a significant probability of developing clinically noticeable diabetic nephropathy and end-stage renal disease. This progression typically happens at a pace of 10 mL/min decline in glomerular filtration rate (GFR) every year. Most laboratories provide glomerular filtration rate (GFR), which is estimated (eGFR) based on serum creatinine levels. An eGFR of ≥90 mL/min/1.73 m2 is considered normal. A patient has stage 2 diabetic nephropathy after their eGFR falls below that cut-off. When nephropathy is identified, hypertension and retinopathy are frequently present. Genetics, early-stage hyperglycaemia, late-stage hypertension, and maybe the amount of protein in the diet are risk factors that predispose to the development of diabetic nephropathy connect to elevated glomerular intracapillary pressure. Protein restriction in the diet may delay the rate at which kidney impairment develops in diabetics with nephropathy that is clinically evident.[30]

Pregnancy-related high blood sugar levels

1. **Testing or evaluation**

- It is advised to use broad screenings.
- Risk factors should not be the basis for screening (they can miss 50% of cases).
- Diabetes should not be employed as a diagnostic tool.
- If screening results are normal at first, it should be done as soon as possible (for example, during the first trimester when scheduling blood tests). If not, it should be done again in 24-28 weeks.
- FIGO, IADPSG, WHO, and IDF advocate testing for hyperglycaemia in one step as opposed to doing separate screening tests and diagnostic tests thereafter.
- Alternative screening methods are recognized globally and include a complete 75 g-OGTT for patients who can handle the glucose challenge or a fasting blood sugar test during the first trimester. Ongoing study is being done in this area.
- It is most likely Type 1 or Type 2 diabetes if discovered during the first trimester of pregnancy.
- The reference values for the diagnosis of gestational diabetes (GDM) and diabetes in pregnancy (DIP) are displayed in the table below. The diagnosis is made once one result is abnormal.

- The reference values for the diagnosis of gestational diabetes (GDM) and diabetes in pregnancy (DIP) are displayed in the table below. The diagnosis is made once one result is abnormal.
- The reference values for the diagnosis of gestational diabetes (GDM) and diabetes in pregnancy (DIP) are displayed in the table below. The diagnosis is made once one result is abnormal.
- The reference values for the diagnosis of gestational diabetes (GDM) and diabetes in pregnancy (DIP) are displayed in the table below. The diagnosis is made once one result is abnormal.
- The reference values for the diagnosis of gestational diabetes (GDM) and diabetes in pregnancy (DIP) are displayed in the table below. The diagnosis is made once one result is abnormal.[31]

Table 1: OGTT criteria (WHO, FIGO, IADPSG) for determining the presence of diabetes with complications.

75 G-OGTT	Normal	GDM, or Neonatal diabetes, is a form of diabetes.	Pregnant Mellitus with Diabetes (DIP)
FBS	< 92 mg/ml	92-125 mg/ml	>126 mg/dl
1 hr post	< 180mg/ml	>10 mmo/l	
2 hr post	<153 mg/ml	153-199 mg/ml	>200 mg/dl

The gestational period diabetes Prevention

1. Managing of Habits as well as Health

Upon being diagnosed, the course of treatment consists of medical nutrition therapy, exercise, and weight management based on presentational weight, it also involves glucose monitoring with the goal of meeting the Fifth International Workshop-Conference on Gestational Diabetes Mellitus' recommended targets.[32]

- Blood sugar levels after fasting <95 mg/dL (5.3 mmol/L) and either
- Blood sugar level one hour after meal <140 mg/dL (7.8 mmol/L)
- The sugar glucose after two hours of eating < 120 mg/dL (6.7 mmol/L).
- For gestational diabetes treated with insulin, the glycaemic target lower limits mentioned above for pre-existing diabetes apply. Studies indicate that between 70 and 85 percent of individuals diagnosed with GDM under Carpenter-Coustan criteria can control their condition with lifestyle modifications alone; if the lower diagnostic thresholds from the

International Association of the Diabetes and Pregnancy Study Groups are applied, this percentage is likely to be even higher.[33]

Dietary Treatments for ailments

A tailored dietary plan created by a registered dietitian (RDN) with experience managing GDM and the expectant patient is known as medical diet treatment for GDM.[34,35]

The 2009 College of Medical criteria state that the meal plan should have enough calories to support increased weight, glycaemic objectives, and mother and fatal/neonatal welfare.[36]

Exercise

A fitness therapy was shown to enhance glucose management and reduce the need to start insulin or the amount of insulin required, according to a systematic review. The kinds of exercise that were effective (resistance, aerobic, or both) and the amount of time spent exercising (20–50 minutes per day, two–seven days per week at a moderate level) varied.[37]

Therapeutic Medicine

A review from the U.S. Preventive Services Task Force summarizes two major randomized studies that show improved perinatal outcomes when GDM is treated with lifestyle changes and insulin. In the United States, insulin is the first medication that is advised for the treatment of GDM. Even if various RCTs support metformin's low efficacy.[38]

And glyburide in lowering blood sugar levels for the treatment of GDM, although due to their ability to cross the placenta and the lack of information regarding their long-term safety for offspring, these medications are not advised as first-line treatments for GDM.[39]

Sulfonylureas

Given their ability to cross the placenta, sulfonylureas have been linked to a higher risk of hypoglycaemia in new-borns. Glyburide concentrations in umbilical cord plasma are roughly 50–70% of mother levels.[40] In meta-analyses and systematic reviews, glyburide was associated with a higher rate of neonatal hypoglycaemia, macrosomia, and increased neonatal abdominal circumference than insulin or metformin.[41] An analysis using a composite outcome of new-born hypoglycaemia, macrosomia, and hyperbilirubinemia failed to find that glycoburide was no inferior to insulin. There are no long-term safety data available for progeny exposed to glyburide.[42]

Metformin

Metformin was associated with a lower risk of neonatal hypoglycaemia and less maternal weight gain than insulin in systematic reviews.[43] Nonetheless, metformin easily crosses the placenta, resulting in levels of the drug in umbilical cord blood that are at least as high as levels in concurrent mother blood.[44] Compared to the 9-year-old offspring exposed to insulin, those exposed to metformin for the treatment of GDM in the Auckland cohort were heavier and had a greater ratio of height to waist and waist circumference, according to analyses of the 7- to 9-year-old descendants in the Metformin in Fatal Diabetes: The Offspring Follow-Up (MiG TOFU) learning.[45]

CONCLUSIONS

GDM, the most frequent metabolic disorder during pregnancy, continues to have a significant negative impact on global health. It is typified by high blood sugar levels throughout pregnancy and is so important to the health of pregnant mothers and their unborn infants that it warrants more research and consideration. The review clarified the short- and long-term effects of gestational diabetes mellitus on expectant mothers. The immediate effects include an increased risk of gestational hypertension, caesarean sections, and other issues related to the foetus. The long-term effects of gestational diabetes mellitus (GDM) include a higher chance of type 2 diabetes after delivery, underscoring the significance of ongoing monitoring and care for affected mothers. Moreover, the impact of GDM on progeny is a very concerning issue. This review emphasizes the increased risk that children of mothers with GDM experience. Of acquiring diseases that can last into adulthood, like insulin resistance, obesity, and hypertension. For proactive management and prevention, it is essential to comprehend these consequences for intergenerational health. In order to properly treat GDM, a multimodal strategy is needed. This strategy entails close blood glucose monitoring, dietary adjustments, consistent exercise, and, if required, medication interventions. Working together, with a focus on education and individualized care, healthcare providers and pregnant moms can effectively manage gestational diabetes mellitus. All women with GDM should receive dietary counselling from a clinical dietitian, as this is the mainstay of GDM treatment.

REFERENCES

1. E. U. Alejandro, Therriz P. Mamerto, Grace Chung, Adrian Villavieja, Nawirah Lumna Gaus, Elizabeth Morgan and Maria Ruth B. Pineda-Cortel, "Gestational Diabetes

Mellitus: A Harbinger of the Vicious Cycle of Diabetes," *International journal of molecular science*, 15 July, 2020; 21(14).

2. M. A. Hanson, P. D. Gluckman, R. C. Ma, P. Matzen and R. G. Biesma., "Early life opportunities for prevention of diabetes in low and middle income countries," *BMC Public Health*, 23 November 2012; 12(10250).
3. Y. Q. P. W. C. M. S. B. Z. A. J. G. H. Ravi Retnakaran, "Glucose Intolerance in Pregnancy and Postpartum Risk of Metabolic Syndrome in Young Women," *The Journal of Clinical Endocrinology & Metabolism*, 1 February, 2010; 95(2): 670–677.
4. S. P. Mary Byrn, "The relationship betweem gestational and diabetes Antenatal depression," *Journal of Obstetric, Gynecologic & Neonatal Nursing*, March, 2025; 44(2): 246-255.
5. L. P. L. S. Z. O. Peng Chiong Tan, "The 50-g glucose challenge test and pregnancy outcome in a multiethnic Asian population at high risk for gestational diabetes," *International Journal of Gynecology & Obstetrics*, 19 January, 2009; 105(1): 50-55.
6. H. X. &. K. A. p. Thomas A. Buchanan, "Gestational diabetes mellitus: risks and management during and after pregnancy," *Nature Reviews Endocrinology*, 2012; 8: 639–649.
7. E. Metzge, "International Association of Diabetes and Pregnancy Study Groups Recommendations on the Diagnosis and Classification of Hyperglycemia in Pregnancy," *Diabetes Care*, 2012; 33(3): 676–682.
8. M. P. Dana Dabelea, M. Janet K. Snell-Bergeon, P. Cynthia L. Hartsfield, M. Kimberly J. Bischoff, M. P. Richard F. Hamman and M. Robert S. McDuffie, "Increasing Prevalence of Gestational Diabetes Mellitus (GDM) Over Time and by Birth Cohort: Kaiser Permanente of Colorado GDM Screening Program," *Diabetes Care*, 1 March, 2005; 28(3): 579–584.
9. H. Xiang, S. L. Kjos, M. Takayanagi, E. Trigo and T. A. Buchanan, "Detailed Physiological Characterization of the Development of Type 2 Diabetes in Hispanic Women With Prior Gestational Diabetes Mellitus," *Diabetes Care*, 1 octomber, 2010; 59(10): 2625–2630.
10. P. Anny H. Xiang, M. Miwa Kawakubo, M. Enrique Trigo, M. Siri L. Kjos and M. Thomas A. Buchanan, "Declining β-Cell Compensation for Insulin Resistance in Hispanic Women With Recent Gestational Diabetes Mellitus: Association with changes in weight, adiponectin, and C-reactive protein," *Diabetes Care*, February, 2010; 33(2): 396–401.

11. M. M. Teresa A. Hillier, M. Kathryn L. Pedula, B. Mark M. Schmidt, A. B. C. Judith A. Mullen, M. M. Marie-Aline Charles and M. David J. Pettitt, "Childhood Obesity and Metabolic Imprinting: The ongoing effects of maternal hyperglycemia," *Diabetes Care*, September, 2007; 30(9): 2287–2292.
12. "Mild glucose intolerance in pregnancy and risk of cardiovascular disease: a population-based cohort study," *Canadian Medical Association Journal* , 15 September, 2009; 181(6-7): 371-376.
13. R. R. a. B. R. Shah, "Mild glucose intolerance in pregnancy and risk of cardiovascular disease: a population-based cohort study," *Canadian Medical Association Journal*, 15 September, 2009; 181(6-7): 371-376.
14. S. U. J. &. R. R. Sullivan, "Gestational Diabetes: Implications for Cardiovascular Health," *Current Diana Reports*, February, 2012; 43–52.
15. H. M. S. G. R. A. S L Boulet, "1372Fetal macrosomia, varyingly characterized as birthweight of >4000, >4500, or >5000 g, is associated with nu-merous perinatal and maternal complications.1-7Past re-search indicates that the incidence of macrosomia in theUnited States has been increasin," *Journal of Obstetrics and Gynaecology*, 2 July, 2009; 24(6): 622-629.
16. B. Y. M. M. L. H. I. V. Lazer S, "Complications associated with the macrosomic fetus," *Journal Of Reproductive Medicine*, June 1986; 31(6).
17. M. ,. B. M. M. M. Hugh M. Ehrenberg, "The influence of obesity and diabetes on the prevalence of macrosomia," *American Journal Of Obstetrics Gynaecology*, September, 2004; 191(3): 964-968.
18. M. U. ,. .. B. Nicholas P. Illsleya, "Human placental glucose transport in fetoplacental growth and metabolism," *BBA - Molecular Basis of Disease*, 1 February, 2020; 1866(2).
19. T. L. P. a. J. Fredrick J. Rosario, "Activation of placental insulin and mTOR signaling in a mouse model of maternal obesity associated with fetal overgrowth," *American Journal Of Physiology*, 1 January, 2016; 87-93.
20. C. G. M. J. H. S. S. N. M. Karen M Logan, "Diabetes in pregnancy and infant adiposity: systematic review and meta-analysis," *BMJ Journal*,120(1).
21. M. G. R. A. R. M. S. H. M. S. M. P. a. P. M. M. Sheree L. Boulet, "Macrosomic births in the United States: Determinants,outcomes, and proposed grades of risk," *American Journal of Obstetrics Gynaecology*, octomber, 2004; 188(5).

22. M. R. J. R. D. T. J. B. L V McFarland, "Erb/Duchenne's palsy: a consequence of fetal macrosomia and method of delivery," *Obstetrics and Gynaecology*, December, 1986; 68(6).
23. F. D. F. M. B. C. S. J. K. Hemant K Satpathy 1, "Maternal obesity and pregnancy," *Postgraduate Medicine*, 15 September, 2008; 120(3): 1-9.
24. "Gestational diabetes mellitus and long-term consequences for mother and offspring," *Diabetologia*, 12 May, 2016; 59: 1396–1399.
25. K. D. L. R. I. G. Holt, "The use of oral hypoglycaemic agents in pregnancy," *Diabetic Medicine*, 4 December, 2013; 31(3): 282-291.
26. W. C. K. Peter H. Bennett, "Early detection and intervention in diabetes mellitus," *Journal of Chronic Diseases*, 37(8): 653-666.
27. J. W. Farquhar, "The Pregnant Diabetic and her Newborn: Problems and Management," *Pediatrics*, August 1968; 42(2).
28. M. E.Albert Reece, M. Donald R. Coustan, M. John P. Hayslett, P. Theodore Holford, R. Jeanne Coulehan and M. Theresa Z. O'Connor, "Diabetic nephropathy: Pregnancy performance and fetomaternal outcome," *American Journal OF Obstetrics and Gynaecology*, July, 1988; 159(1): 56-66.
29. "Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes—2018," *Diabetes Care*, 1 January, 2018; 1: 105-118.
30. M. E. W. M. R. L. S. M. R. P. R. M. a. H. R. J. M. Kathleen Zeller, "Effect of Restricting Dietary Protein on the Progression of Renal Failure in Patients with Insulin-Dependent Diabetes Mellitus," *New England Journal of Medicine*, 10 January, 1991; 324(2).
31. D. o. W. H. M. o. Health, Diabetes Mellitus and Pregnancy, 2018.
32. M. Boyd E. Metzger, M. Thomas A. Buchanan, M. Donald R. Coustan, M. P. Alberto de Leiva, M. M. F. David B. Dunger, M. F. David R. Hadden, M. Moshe Hod, M. John L. Kitzmiller, M. Siri L. Kjos, D. Jeremy N. Oats, M. David J. Pettitt and D, "Summary and Recommendations of the Fifth International Workshop-Conference on Gestational Diabetes Mellitus," *Diabetes Care*, July, 2007; 30(2): 251-160.
33. M. Karli Mayo, M. Nir Melamed and P. F. D. Hilde Vandenberghe, "The impact of adoption of the International Association of Diabetes in Pregnancy Study," *American Journal of Obstetrics and Gynecology*, 01 02, 2015; 212(2): 224.e1-224.e9.
34. S. H. M. S. V. R. A. Crowther, "Different types of dietary advice for women with gestational diabetes mellitus," *Cochrane Database of Systematic Reviews*, 25 February, 2017.

35. L. V. Viana, J. L. Gross and M. J. Azevedo, "Dietary Intervention in Patients With Gestational Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Clinical Trials on Maternal and Newborn Outcomes," *Diabetes Care*, 1 December, 2014; 37(12): 3345–3355.
36. K. M. R. a. A. L. Yaktine, "Weight Gain During Pregnancy," National Academies Press, 2009.
37. J. A. Laredo-Aguilera and M. G.-B.,. A. R.-S.,. I. C.-C.,. a. M. C.-T.,. ORCID, "Physical Activity Programs during Pregnancy Are Effective for the Control of Gestational Diabetes Mellitus," *International Journal Of Environmental science and Public Health*, 2020; 17(17).
38. Q. L. F. Juan Gui, "Metformin vs Insulin in the Management of Gestational Diabetes: A Meta-Analysis," *Plos One*, 27 May, 2013; 8(5).
39. M. P. a. M. T. M. Aaron B. Caughey, "ACOG Practice Bulletin No. 190: Gestational Diabetes Mellitus," *Obstetrics & Gynecology*, February, 2018; 131(2): e49-e64.
40. X. M. S. N. K. K. J. U. G. H. S. C. M. M. D. M. J. U. E. K. D. B. C. C. M. A. W. S. D. C. MF Hebert, "Are We Optimizing Gestational Diabetes Treatment With Glyburide? The Pharmacologic Basis for Better Clinical Practice," *Clinical Pharmacology and Therapeutics*, 18 March 2009; 85(6).
41. C. E. A.,. E. O. Jane L. Tarry-Adkins, "Comparative impact of pharmacological treatments for gestational diabetes on neonatal anthropometry independent of maternal glycaemic control: A systematic review and meta-analysis," *Plos Medicine*, 22 May, 2020.
42. M. P. Marie-Victoire Sénat, M. Helene Affres, M. Alexandra Letourneau, M. Magali Coustols-Valat, M. Marie Cazaubiel, M. Helene Legardeur, M. Julie Fort Jacquier, M. Nathalie Bourcigaux, M. Emmanuel Simon, M. Anne Rod, M. Isabelle Héron and Virg, "Effect of Glyburide vs Subcutaneous Insulin on Perinatal Complications Among Women With Gestational Diabetes," *JAMA*, 2018; 319(17): 1773–1780.
43. "Glibenclamide, metformin, and insulin for the treatment of gestational diabetes: a systematic review and meta-analysis," 21 January, 2015; 350(102).
44. M. K. Z. M. O. S. M. P. M. C. M. P. Eszter Vanky, "Placental passage of metformin in women with polycystic ovary syndrome," *Fertility and Sterility*, May, 2005; 83(5): 1575-1578.

45. E. C. R.,. L. D. P.,. J. L. V. O. S. C.,. W. M. H. Janet A Rowan, "Metformin in gestational diabetes: the offspring follow-up (MiG TOFU): body composition and metabolic outcomes at 7–9 years of age," 6(1).